Skip to content

ImmunityBio

US · IBRX #1397 by market cap Listed 1970
6.02 -0.55 -8.37%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:59

Price chart

Pre-market 6.42 -2.28%
After-hours 6.08 +1.08%
Overnight 6.50 -1.07%
10.515.986.022026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on IBRX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +87.4% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 11.9% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days B → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability C

How much profit the business keeps from each dollar of sales and capital.

Gross margin 99.3% Better than 99%
Operating margin -226.0% Better than 5%
Net margin -310.2% Better than 4%
Momentum C+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -22.7% Better than 26%
6-month return -16.6% Better than 31%
12-month return (ex latest month) 295.2% Better than 99%
Distance below 52-week high 51.6% Better than 17%
Financial Health C-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 5.1x Better than 87%
Debt to assets 103.2% Better than 1%
Interest coverage -2.1x Better than 20%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 136.7% Better than 89%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W +0.00%
1M -31.36%
3M -23.21%
6M -25.22%
YTD +204.04%
1Y +198.02%
3Y +48.64%
5Y -6.38%

Key statistics

Price & volume

Prev close
6.57
Open
6.41
Day range
6.00 - 6.53
Avg price
6.17
Volume
10.64M
Turnover
65.67M
Amplitude
8.07%
52-week range
1.95 - 12.43

Valuation

P/E
-15.84
P/E (TTM)
-5.68
P/B
-5.58
EPS
-0.38
Net profit
-404.25M
Net assets
-1.15B

Share structure

Market cap
6.40B
Float cap
2.47B
Shares out
1.06B
Float shares
410.68M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 39% of range
1.95 12.43

51.6% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-30.73M net over the window

Short interest

Shares short
126.08M
As of
2026-10-30

Frequently asked questions

What is the current stock price of ImmunityBio (IBRX)?

ImmunityBio last traded at 6.02. This page shows a periodic quote snapshot. Check the displayed quote time.

What is ImmunityBio's market cap?

About 6.40B.

What is the P/E ratio of ImmunityBio?

The trailing twelve-month P/E is -5.68. The Valuation tab shows it against the stock's own five-year range.

Does ImmunityBio pay a dividend?

ImmunityBio does not currently pay a regular dividend.

Is ImmunityBio a buy according to analysts?

The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 14.25, which implies 136.7% upside from the current price. This is not investment advice.

What is ImmunityBio's StockVane Quant Rating?

The StockVane Momentum strategy currently rates ImmunityBio a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:59:40 · For reference only, not investment advice and not tailored to your situation.

ImmunityBio discussion 0 comments

Add a comment